Indo Us Bio-Tech Ltd

Indo US Bio Tech Ltd. announced that its board met on Saturday, September 5, 2026, and approved the calling of its 22nd Annual General Meeting for the financial year ended March 31, 2026, to be held on September 30, 2026, via video conferencing or other audio-visual means, and appointed M/s. Bhagat & Associates as statutory auditors for five years from the conclusion of the meeting, subject to member approval. The company also appointed M/s. Amrish Gandhi & Associates as the scrutinizer for the e-voting process, and declared a book closure from September 23, 2026, to September 30, 2026.

Indo Us Bio Tech Limited will hold a board meeting on Wednesday, August 12, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026, and other corporate matters, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for insiders, which closed on July 1, 2026, will remain closed until 48 hours after the dissemination of the unaudited standalone financial results for the quarter ended June 30, 2026.

Net profit of Indo US Bio-Tech declined 46.47% to Rs 1.97 crore in the quarter ended March 2026 as against Rs 3.68 crore during the previous quarter ended March 2025. Sales declined 22.05% to Rs 26.02 crore in the quarter ended March 2026 as against Rs 33.38 crore during the previous quarter ended March 2025. For the full year,net profit declined 19.36% to Rs 13.12 crore in the year ended March 2026 as against Rs 16.27 crore during the previous year ended March 2025. Sales rose 6.36% to Rs 110.44 crore in the year ended March 2026 as against Rs 103.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales26.0233.38 -22 110.44103.84 6 OPM %12.4113.69 -15.4018.24 - PBDT2.654.43 -40 14.8217.63 -16 PBT2.383.87 -39 13.9216.53 -16 NP1.973.68 -46 13.1216.27 -19 Powered by Capital Market - Live

Indo US Bio-Tech will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Net profit of Indo US Bio-Tech declined 40.59% to Rs 3.00 crore in the quarter ended December 2025 as against Rs 5.05 crore during the previous quarter ended December 2024. Sales declined 3.23% to Rs 22.80 crore in the quarter ended December 2025 as against Rs 23.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales22.8023.56 -3 OPM %18.2023.47 - PBDT3.395.17 -34 PBT3.175.01 -37 NP3.005.05 -41 Powered by Capital Market - Live

Indo US Bio-Tech will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live

SVP Global Textiles Ltd, SMS Pharmaceuticals Ltd, Igarashi Motors India Ltd and BIGBLOC Construction Ltd are among the other gainers in the BSE's 'B' group today, 26 November 2025.Indo US Bio-Tech Ltd surged 19.98% to Rs 132.4 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 2811 shares were traded on the counter so far as against the average daily volumes of 971 shares in the past one month. SVP Global Textiles Ltd soared 19.83% to Rs 5.68. The stock was the second biggest gainer in 'B' group. On the BSE, 1.33 lakh shares were traded on the counter so far as against the average daily volumes of 33706 shares in the past one month. SMS Pharmaceuticals Ltd spiked 15.44% to Rs 316.3. The stock was the third biggest gainer in 'B' group. On the BSE, 3.32 lakh shares were traded on the counter so far as against the average daily volumes of 34060 shares in the past one month. Igarashi Motors India Ltd gained 15.38% to Rs 501.9. The stock was the fourth biggest gainer in 'B' group. On the BSE, 2.74 lakh shares were traded on the counter so far as against the average daily volumes of 2142 shares in the past one month. BIGBLOC Construction Ltd exploded 14.16% to Rs 65.3. The stock was the fifth biggest gainer in 'B' group. On the BSE, 59903 shares were traded on the counter so far as against the average daily volumes of 9205 shares in the past one month. Powered by Capital Market - Live

Net profit of Indo US Bio-Tech declined 20.87% to Rs 3.45 crore in the quarter ended September 2025 as against Rs 4.36 crore during the previous quarter ended September 2024. Sales rose 39.15% to Rs 30.85 crore in the quarter ended September 2025 as against Rs 22.17 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales30.8522.17 39 OPM %13.4823.14 - PBDT3.774.63 -19 PBT3.564.45 -20 NP3.454.36 -21 Powered by Capital Market - Live

Indo US Bio-Tech will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

Indo US Bio-Tech will hold a meeting of the Board of Directors of the Company on 14 October 2025.Powered by Capital Market - Live